Dr. Reddy's Laboratories Ltd. (RDY)

41.33
0.48 1.18
NYSE : Health Technology
Prev Close 40.85
Open 41.50
Day Low/High 41.24 / 41.85
52 Wk Low/High 28.13 / 40.20
Volume 88.22K
Avg Volume 211.80K
Exchange NYSE
Shares Outstanding 166.00M
Market Cap 6.64B
EPS 0.90
P/E Ratio 43.99
Div & Yield 0.27 (0.73%)
IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

IMPORTANT SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

Scott + Scott, LLP, a global investor rights law firm, has opened an investigation to determine whether Dr.

Dr. Reddy's Laboratories Limited's ("Company") Board Approves The Proposal For Buyback Of Its Equity Shares

Dr. Reddy's Laboratories Limited's ("Company") Board Approves The Proposal For Buyback Of Its Equity Shares

The Board of Directors of the Company in their meeting held on 17 th February, 2016 has approved a proposal to buyback Equity Shares of the Company, subject to approval by the shareholders, for an aggregate amount not...

Dr. Reddy's Q3 And 9M FY16 Financial Results

Dr. Reddy's Q3 And 9M FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Promius Pharma™ Receives FDA Approval For Sernivo (betamethasone Dipropionate) Spray, 0.05%

Promius Pharma™ Receives FDA Approval For Sernivo (betamethasone Dipropionate) Spray, 0.05%

Dr. Reddy's announced today that its US subsidiary, Promius Pharma TM, LLC, U.

SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

SHAREHOLDER ALERT: Scott + Scott, LLP Investigating Dr. Reddy's Labs (RDY) For Possible Securities Fraud

Scott + Scott, LLP, a global investor rights law firm, has opened an investigation to determine whether Dr.

Dr. Reddy's Laboratories Receives USFDA Tentative Approval For Zenavod™ (doxycycline) Capsules, 40 Mg For The Treatment Of Rosacea In Adults

Dr. Reddy's Laboratories Receives USFDA Tentative Approval For Zenavod™ (doxycycline) Capsules, 40 Mg For The Treatment Of Rosacea In Adults

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today the U.

Dr. Reddy's Laboratories Ltd. Receives FDA Approval For ZEMBRACE™SymTouch™ (sumatriptan Succinate) Injection For The Acute Treatment Of Migraines In Adults

Dr. Reddy's Laboratories Ltd. Receives FDA Approval For ZEMBRACE™SymTouch™ (sumatriptan Succinate) Injection For The Acute Treatment Of Migraines In Adults

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the U.

Dr. Reddy's To Release Q3FY16 Results On Feb 9, 2016; Earnings Call Slated For Feb 9, 6:30 PM IST / 8:00 AM EST

Dr. Reddy's To Release Q3FY16 Results On Feb 9, 2016; Earnings Call Slated For Feb 9, 6:30 PM IST / 8:00 AM EST

Dr. Reddy's Laboratories (NYSE: RDY; NSE: DRREDDY; BSE: 500124) will announce results for the Third Quarter and 9 months ended December 31, 2015 on Tuesday, February 9, 2016 after the Board Meeting.

Dr. Reddy's Announces The Relaunch Of Esomeprazole Magnesium Delayed-Release Capsules, USP

Dr. Reddy's Announces The Relaunch Of Esomeprazole Magnesium Delayed-Release Capsules, USP

Dr. Reddy's today announced the re-launch of its Esomeprazole Magnesium Delayed-Release Capsules, a therapeutic equivalent generic version of Nexium® (esomeprazole magnesium) Delayed-Release capsules in the US market.

Despite Legal Troubles, Is Dr. Reddy's a Buy?

Despite Legal Troubles, Is Dr. Reddy's a Buy?

Does the mess around Dr. Reddy's make it a good buying opportunity

Dr. Reddy's Issues A Clarification Note

Dr. Reddy's Issues A Clarification Note

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY): Reacting to certain statements that appeared in the media today relating to its corporate governance practices, Dr.

Dr. Reddy's Announces The Completion Of Fondaparinux Intellectual Property Purchase

Dr. Reddy's Announces The Completion Of Fondaparinux Intellectual Property Purchase

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) today announced that it has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic...

Dr Reddy Laboratories (RDY) Showing Signs Of Perilous Reversal Today

Dr Reddy Laboratories (RDY) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a "perilous reversal" (up big yesterday but down big today) candidate

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong on high relative volume candidate

If a Market Crash Is Coming, Here's What to Do With Your Stocks, Bonds and Mutual Funds

If a Market Crash Is Coming, Here's What to Do With Your Stocks, Bonds and Mutual Funds

U.S. markets seem to be running out of steam. If markets crash, here are the criteria to check when deciding whether to sell a stock, mutual fund or bond.

Dr Reddy Laboratories (RDY) Weak On High Volume

Dr Reddy Laboratories (RDY) Weak On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a weak on high relative volume candidate

Statement From Dr. Reddy's Regarding The Receipt Of Temporary Restraining Order (TRO) For Esomeprazole Capsules

Statement From Dr. Reddy's Regarding The Receipt Of Temporary Restraining Order (TRO) For Esomeprazole Capsules

Dr. Reddy's Laboratories (NYSE: RDY) in a statement issued today said that it has been made aware of an order passed by the District Court of Delaware, USA, granting a Temporary Restraining Order (TRO) with immediate effect...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dr. Reddy's Laboratories Ltd. - RDY

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Dr. Reddy's Laboratories Ltd. - RDY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Dr.

Dr. Reddy's To Hold A Conference Call On Nov 9, 2015 At 4.00 PM IST / 5.30 AM EST

Dr. Reddy's To Hold A Conference Call On Nov 9, 2015 At 4.00 PM IST / 5.30 AM EST

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will hold a Conference Call on November 9, 2015 to clarify investors' queries on the Warning Letter issued by the US FDA dated November 05, 2015.

5 Toxic Stocks to Sell Now

5 Toxic Stocks to Sell Now

Here's a technical look at five stocks you need to unload from your portfolio in November.

Dr. Reddy's Statement On The Receipt Of Warning Letter From US FDA

Dr. Reddy's Statement On The Receipt Of Warning Letter From US FDA

Dr. Reddy's Laboratories (BSE: 500124) (NYSE: RDY) today issued a statement acknowledging that it has received a warning letter issued by the US FDA dated November 05, 2015 relating to its API manufacturing facilities...

Biocodex Inks Distribution Pact With Dr. Reddy's To Market Its Flagship Products In Romania

Biocodex Inks Distribution Pact With Dr. Reddy's To Market Its Flagship Products In Romania

Dr. Reddy's Laboratories (NYSE: RDY) has entered into a strategic alliance with Biocodex to market and distribute Biocodex products in the Romanian market.

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Strong And Under The Radar: Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong and under the radar candidate

Dr. Reddy's Strengthens OTC Portfolio - Launches Nise D Spray

Dr. Reddy's Strengthens OTC Portfolio - Launches Nise D Spray

Dr. Reddy's today announced the launch of Nise D Spray, emphasizing its strategic intent of being a player of substance in the Indian OTC (Over The Counter) space.

Dr. Reddy's Q2 And H1 FY16 Financial Results

Dr. Reddy's Q2 And H1 FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q2FY16 Results On Oct 29, 2015 // Earnings Call Slated For Oct 29, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q2FY16 Results On Oct 29, 2015 // Earnings Call Slated For Oct 29, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half year ended September 30, 2015 on Thursday, October 29, 2015 after the Board Meeting.

TheStreet Quant Rating: B (Buy)